Dengue Literature Review

Garcia2009 - Long-term Clinical Symptoms Post-Dengue

5 min read

Garcia2009 - Long-term Clinical Symptoms Post-Dengue

Full citation: García G, González N, Pérez AB, Sierra B, Aguirre E, Rizo D, Izquierdo A, Sánchez L, Díaz D, Lezcay M, Pacheco B, Hirayama K, Guzmán MG. Long-term persistence of clinical symptoms in dengue-infected persons and its association with immunological disorders. International Journal of Infectious Diseases 15 (2011): e38–e43. https://doi.org/10.1016/j.ijid.2010.09.008

Raw file: [[raw/garcia2009.pdf]]

Summary

This study investigated the persistence of clinical symptoms in adults 2 years after symptomatic dengue infection during the 2006 Cuban DENV-4 epidemic. Ninety-seven hospitalized patients (68 DF, 29 DHF/DSS) were followed up in 2008 alongside 42 individuals with asymptomatic infection. Over half (56.7%) of symptomatic patients reported ongoing clinical manifestations, most prominently musculoskeletal pain, neurological complaints, and general malaise. No persistent symptoms were reported among asymptomatic patients, and all participants showed normal psychological and cognitive function on formal assessment.

The study examined immunological and genetic correlates of these sequelae. High anti-dengue IgG titers and the FcγRIIa-HH genotype were both significantly associated with persistent symptoms. A subset of 26 symptomatic individuals underwent autoimmune marker screening; 76.9% showed at least one abnormality (elevated CRP, immune complexes, or ANA), leading the authors to propose that post-dengue syndrome may be autoimmune in origin, driven by impaired immune complex clearance in individuals carrying the HH genotype.

The authors describe this as the first evidence of persistent dengue sequelae extending to 2 years post-infection, and note the findings have implications for vaccine development given the role of FcγRIIa in antibody-mediated responses.

Study Design

  • Type: Retrospective cohort with cross-sectional follow-up
  • Sample size: 97 symptomatic patients (68 DF, 29 DHF/DSS) + 42 asymptomatic controls; autoimmune marker subset n = 26
  • Setting: Instituto Pedro Kourí (IPK), Havana, Cuba; patients hospitalised during 2006 DENV-4 epidemic, followed up in 2008
  • Population: Adults aged 32–60 years, all with confirmed DENV-4 infection by anti-dengue IgM

Key Findings

  • 55/97 (56.7%) symptomatic patients had persistent clinical symptoms at 2 years post-infection
  • Most common sequelae: muscle pain (30.2%), arthralgia (29.5%), asthenia (23.0%), hand weakness (22.3%), general malaise (20.1%), irritability and memory loss (19.4% each), palpitations (19.4%), dizziness (17.9%), arthropathy (17.3%)
  • 0/42 asymptomatic patients reported any persistent symptoms
  • Persistent symptoms significantly more prevalent in women (65.7%) than men (36.7%), p = 0.008; 44/55 symptomatic individuals were female
  • No association between acute illness severity (DF vs DHF/DSS) and development of sequelae (p = 0.086)
  • Higher anti-dengue IgG titers in those with persistent symptoms (p = 0.041)
  • FcγRIIa-HH genotype associated with persistent symptoms vs HR+RR combined (p = 0.027; OR 2.83, 95% CI 1.01–8.11)
  • HH genotype specifically associated with joint/muscle/bone pain (p = 0.036) and neurological complaints (p = 0.008, Fisher’s exact test)
  • 20/26 (76.9%) symptomatic subset showed ≥1 autoimmune marker alteration
  • IC and CRP elevated in 42.3% each; ANA positive in 23.1%; RF elevated in 3.8%
  • Elevated IC correlated with higher IgG titers (p = 0.042)
  • Most symptomatic patients (21/26) had history of prior dengue infection; 12/26 had tetravalent infection history (DENV-1→2→3→4)

Methods Used

  • ELISA Inhibition Method (anti-dengue IgG titer quantification)
  • PRNT (neutralising antibody assessment across all 4 serotypes; used to reconstruct prior infection sequence)
  • FcγRIIa Genotyping (nested PCR to determine R/R131, H/H131, R/H131 variants)
  • Indirect Immunofluorescence ANA Test on rat liver tissue (not HEp-2 cells — an older, less sensitive substrate; this makes direct comparison with HEp-2-based healthy-population ANA estimates methodologically imprecise)
  • Immune complex detection by PEG turbidimetric assay
  • Complement C3/C4, rheumatoid factor, CRP by immunoturbidimetric assay (Roche Hitachi analyser)
  • Standardised symptom questionnaire and psychological interview

Entities Mentioned

  • DENV-4 (epidemic serotype; all confirmed infections were DENV-4)
  • FcγRIIa Receptor (genetic polymorphism central to findings)

Concepts Addressed

Relevance & Notes

This is the first paper in the wiki and establishes the existence and clinical character of long-term dengue sequelae. The finding that acute illness severity (DF vs DHF) does not predict sequelae is notable — it implies post-dengue syndrome is not simply a continuation of severe disease. The strong female predominance parallels known patterns in autoimmune diseases generally.

Limitations noted by the authors: no autoimmune marker comparison between symptomatic and asymptomatic groups (only symptomatic patients were tested for autoimmune markers); sample restricted to adults; single epidemic/serotype context (DENV-4, Cuba 2006). The study was cross-sectional at follow-up, so symptom onset timing within the 2-year window is not established.

The IPK Havana group (Guzmán, García, Pérez, Sierra) is prolific in this area; their work on FcγRIIa and Cuban epidemics will likely appear in future ingests.

The companion paper Garcia2010 - Asymptomatic Dengue FcγRIIa Polymorphism uses the identical cohort (97 symptomatic + 42 asymptomatic, same 2006 DENV-4 epidemic) to show that FcγRIIa-HH is a risk factor not just for severe disease but for symptomatic infection itself — with asymptomatic individuals showing only 9.1% HH vs 51.5% in DHF. Together, the two papers build a coherent picture: HH genotype gates both acute symptom expression and long-term sequelae.

Questions Raised

  • Do children show similar post-dengue sequelae? The authors explicitly flag this as unexplored.
  • Is the female predominance of sequelae replicated in non-Cuban or non-DENV-4 cohorts?
  • Do asymptomatic individuals develop any subclinical autoimmune changes not detectable by symptom questionnaire?
  • Does the number of prior infections (secondary, tertiary, quaternary) show a dose–response relationship with sequelae severity or type?
  • Do sequelae resolve beyond 2 years, or persist longer?
  • Would immunosuppressive intervention during or after acute dengue affect long-term outcomes?

Graph View

Backlinks